HALO Annual CFF
-$407.99 M
-$770.36 M-212.59%
31 December 2023
Summary:
As of January 22, 2025, HALO annual cash flow from financing activities is -$407.99 million, with the most recent change of -$770.36 million (-212.59%) on December 31, 2023. During the last 3 years, it has fallen by -$301.70 million (-283.86%). HALO annual CFF is now -212.59% below its all-time high of $362.37 million, reached on December 31, 2022.HALO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Quarterly CFF
$18.56 M
+$9.08 M+95.75%
30 September 2024
Summary:
As of January 22, 2025, HALO quarterly cash flow from financing activities is $18.56 million, with the most recent change of +$9.08 million (+95.75%) on September 30, 2024. Over the past year, it has increased by +$14.46 million (+352.60%). HALO quarterly CFF is now -94.95% below its all-time high of $367.82 million, reached on June 30, 2022.HALO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO TTM CFF
-$222.37 M
+$14.46 M+6.11%
30 September 2024
Summary:
As of January 22, 2025, HALO TTM cash flow from financing activities is -$222.37 million, with the most recent change of +$14.46 million (+6.11%) on September 30, 2024. Over the past year, it has dropped by -$70.63 million (-46.55%). HALO TTM CFF is now -161.36% below its all-time high of $362.37 million, reached on December 31, 2022.HALO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -212.6% | +352.6% | -46.5% |
| 3 y3 years | -283.9% | +352.6% | -46.5% |
| 5 y5 years | -539.5% | +352.6% | -46.5% |
HALO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -212.6% | at low | -95.0% | +107.4% | -161.4% | +45.5% |
| 5 y | 5-year | -212.6% | at low | -95.0% | +107.4% | -161.4% | +45.5% |
| alltime | all time | -212.6% | at low | -95.0% | +107.4% | -161.4% | +45.5% |
Halozyme Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $18.56 M(+95.7%) | -$222.37 M(-6.1%) |
| June 2024 | - | $9.48 M(-2039.1%) | -$236.83 M(-2.9%) |
| Mar 2024 | - | -$489.00 K(-99.8%) | -$243.86 M(-40.2%) |
| Dec 2023 | -$407.99 M(-212.6%) | -$249.92 M(-6194.1%) | -$407.99 M(+168.9%) |
| Sept 2023 | - | $4.10 M(+67.7%) | -$151.74 M(-9.8%) |
| June 2023 | - | $2.45 M(-101.5%) | -$168.24 M(-185.3%) |
| Mar 2023 | - | -$164.61 M(-2700.9%) | $197.13 M(-45.6%) |
| Dec 2022 | $362.37 M(+365.4%) | $6.33 M(-151.0%) | $362.37 M(+81.2%) |
| Sept 2022 | - | -$12.40 M(-103.4%) | $200.03 M(+31.3%) |
| June 2022 | - | $367.82 M(>+9900.0%) | $152.36 M(-158.6%) |
| Mar 2022 | - | $624.00 K(-100.4%) | -$260.21 M(-434.2%) |
| Dec 2021 | $77.86 M(-173.3%) | -$156.01 M(+159.7%) | $77.86 M(-62.3%) |
| Sept 2021 | - | -$60.07 M(+34.2%) | $206.48 M(-7.3%) |
| June 2021 | - | -$44.76 M(-113.2%) | $222.69 M(-20.8%) |
| Mar 2021 | - | $338.70 M(-1336.2%) | $281.04 M(-364.4%) |
| Dec 2020 | -$106.28 M(-169.4%) | -$27.40 M(-37.5%) | -$106.28 M(-180.8%) |
| Sept 2020 | - | -$43.85 M(-422.6%) | $131.53 M(-15.8%) |
| June 2020 | - | $13.59 M(-128.0%) | $156.14 M(+23.6%) |
| Mar 2020 | - | -$48.62 M(-123.1%) | $126.32 M(-17.6%) |
| Dec 2019 | $153.22 M(-340.2%) | $210.42 M(-1193.1%) | $153.22 M(-302.8%) |
| Sept 2019 | - | -$19.25 M(+18.6%) | -$75.56 M(+3.9%) |
| June 2019 | - | -$16.23 M(-25.3%) | -$72.73 M(-0.2%) |
| Mar 2019 | - | -$21.73 M(+18.4%) | -$72.88 M(+14.2%) |
| Dec 2018 | -$63.80 M(-148.5%) | -$18.35 M(+11.8%) | -$63.80 M(+40.6%) |
| Sept 2018 | - | -$16.42 M(+0.3%) | -$45.36 M(+52.0%) |
| June 2018 | - | -$16.37 M(+29.4%) | -$29.83 M(-124.4%) |
| Mar 2018 | - | -$12.65 M(<-9900.0%) | $122.39 M(-7.0%) |
| Dec 2017 | $131.66 M(-12.6%) | $82.00 K(-109.2%) | $131.66 M(-0.1%) |
| Sept 2017 | - | -$890.00 K(-100.7%) | $131.85 M(-1.0%) |
| June 2017 | - | $135.84 M(-4116.7%) | $133.22 M(+4669.7%) |
| Mar 2017 | - | -$3.38 M(-1312.2%) | $2.79 M(-98.1%) |
| Dec 2016 | $150.62 M(+1050.0%) | $279.00 K(-41.4%) | $150.62 M(-1.0%) |
| Sept 2016 | - | $476.00 K(-91.2%) | $152.07 M(+0.0%) |
| June 2016 | - | $5.42 M(-96.2%) | $152.03 M(+1.1%) |
| Mar 2016 | - | $144.45 M(+8244.7%) | $150.39 M(+1048.2%) |
| Dec 2015 | $13.10 M(-88.6%) | $1.73 M(+296.1%) | $13.10 M(-5.3%) |
| Sept 2015 | - | $437.00 K(-88.4%) | $13.84 M(-2.5%) |
| June 2015 | - | $3.77 M(-47.3%) | $14.20 M(+22.1%) |
| Mar 2015 | - | $7.16 M(+189.6%) | $11.62 M(-89.8%) |
| Dec 2014 | $114.50 M(+356.8%) | $2.47 M(+210.8%) | $114.50 M(-15.2%) |
| Sept 2014 | - | $795.00 K(-33.8%) | $135.10 M(-1.1%) |
| June 2014 | - | $1.20 M(-98.9%) | $136.61 M(+0.9%) |
| Mar 2014 | - | $110.03 M(+377.0%) | $135.35 M(+440.0%) |
| Dec 2013 | $25.06 M | $23.07 M(+901.7%) | $25.06 M(-21.0%) |
| Sept 2013 | - | $2.30 M(-4287.3%) | $31.74 M(+7.7%) |
| June 2013 | - | -$55.00 K(-78.2%) | $29.48 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$252.00 K(-100.8%) | $29.44 M(-73.9%) |
| Dec 2012 | $112.82 M(+2275.8%) | $29.74 M(>+9900.0%) | $112.82 M(+34.8%) |
| Sept 2012 | - | $38.90 K(-143.2%) | $83.68 M(-0.8%) |
| June 2012 | - | -$90.00 K(-100.1%) | $84.34 M(-1.9%) |
| Mar 2012 | - | $83.12 M(>+9900.0%) | $86.00 M(+1711.2%) |
| Dec 2011 | $4.75 M(-92.3%) | $607.00 K(-12.7%) | $4.75 M(-9.8%) |
| Sept 2011 | - | $695.10 K(-56.0%) | $5.26 M(-91.9%) |
| June 2011 | - | $1.58 M(-15.5%) | $64.77 M(+2.4%) |
| Mar 2011 | - | $1.87 M(+66.7%) | $63.23 M(+2.3%) |
| Dec 2010 | $61.82 M(+36.3%) | $1.12 M(-98.1%) | $61.82 M(-0.4%) |
| Sept 2010 | - | $60.20 M(>+9900.0%) | $62.06 M(+1170.2%) |
| June 2010 | - | $34.00 K(-92.7%) | $4.89 M(-88.7%) |
| Mar 2010 | - | $463.50 K(-65.9%) | $43.37 M(-4.4%) |
| Dec 2009 | $45.36 M(+1664.6%) | $1.36 M(-55.1%) | $45.36 M(+1.9%) |
| Sept 2009 | - | $3.03 M(-92.1%) | $44.51 M(+4.4%) |
| June 2009 | - | $38.52 M(+1473.9%) | $42.63 M(+863.5%) |
| Mar 2009 | - | $2.45 M(+375.6%) | $4.42 M(+72.1%) |
| Dec 2008 | $2.57 M(-95.4%) | $514.60 K(-55.0%) | $2.57 M(-9.1%) |
| Sept 2008 | - | $1.14 M(+258.2%) | $2.83 M(+32.2%) |
| June 2008 | - | $319.10 K(-46.2%) | $2.14 M(-94.0%) |
| Mar 2008 | - | $593.60 K(-23.2%) | $35.83 M(-36.0%) |
| Dec 2007 | $56.00 M(+205.3%) | $772.50 K(+70.3%) | $56.00 M(-16.8%) |
| Sept 2007 | - | $453.70 K(-98.7%) | $67.27 M(-4.9%) |
| June 2007 | - | $34.01 M(+63.8%) | $70.77 M(+87.1%) |
| Mar 2007 | - | $20.76 M(+72.4%) | $37.83 M(+106.2%) |
| Dec 2006 | $18.34 M(+11.4%) | $12.04 M(+204.4%) | $18.34 M(-18.1%) |
| Sept 2006 | - | $3.96 M(+271.1%) | $22.41 M(+21.1%) |
| June 2006 | - | $1.07 M(-16.7%) | $18.50 M(+6.1%) |
| Mar 2006 | - | $1.28 M(-92.1%) | $17.44 M(+5.9%) |
| Dec 2005 | $16.47 M(-29.8%) | $16.11 M(>+9900.0%) | $16.47 M(+4.2%) |
| Sept 2005 | - | $51.30 K(+1952.0%) | $15.82 M(-0.3%) |
| June 2005 | - | $2500.00(-99.2%) | $15.86 M(-0.2%) |
| Mar 2005 | - | $310.70 K(-98.0%) | $15.89 M(-32.2%) |
| Dec 2004 | $23.45 M(>+9900.0%) | $15.45 M(>+9900.0%) | $23.45 M(+231.4%) |
| Sept 2004 | - | $99.00 K(+230.0%) | $7.08 M(+1.0%) |
| June 2004 | - | $30.00 K(-99.6%) | $7.01 M(-5.8%) |
| Mar 2004 | - | $7.87 M(-951.8%) | $7.44 M(<-9900.0%) |
| Dec 2003 | $0.00(-100.0%) | -$923.90 K(-3190.0%) | -$100.00(-100.0%) |
| Sept 2003 | - | $29.90 K(-93.5%) | $923.80 K(+3.3%) |
| June 2003 | - | $459.50 K(+5.8%) | $893.90 K(+59.3%) |
| Mar 2003 | - | $434.40 K(>+9900.0%) | $561.30 K(+342.3%) |
| Dec 2002 | $126.90 K(+109.8%) | $0.00(0.0%) | $126.90 K(0.0%) |
| Sept 2002 | - | $0.00(-100.0%) | $126.90 K(0.0%) |
| June 2002 | - | $126.90 K(>+9900.0%) | $126.90 K(>+9900.0%) |
| Mar 2002 | - | $0.00 | $0.00 |
| Dec 2001 | $60.50 K | - | - |
FAQ
- What is Halozyme Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual CFF year-on-year change?
- What is Halozyme Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly CFF year-on-year change?
- What is Halozyme Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM CFF year-on-year change?
What is Halozyme Therapeutics annual cash flow from financing activities?
The current annual CFF of HALO is -$407.99 M
What is the all time high annual CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash flow from financing activities is $362.37 M
What is Halozyme Therapeutics annual CFF year-on-year change?
Over the past year, HALO annual cash flow from financing activities has changed by -$770.36 M (-212.59%)
What is Halozyme Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of HALO is $18.56 M
What is the all time high quarterly CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash flow from financing activities is $367.82 M
What is Halozyme Therapeutics quarterly CFF year-on-year change?
Over the past year, HALO quarterly cash flow from financing activities has changed by +$14.46 M (+352.60%)
What is Halozyme Therapeutics TTM cash flow from financing activities?
The current TTM CFF of HALO is -$222.37 M
What is the all time high TTM CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cash flow from financing activities is $362.37 M
What is Halozyme Therapeutics TTM CFF year-on-year change?
Over the past year, HALO TTM cash flow from financing activities has changed by -$70.63 M (-46.55%)